Clinical Trial Update: Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating early initiation of empagliflozin in cardiogenic shock and its effects on mortality, rehospitalization, left ventricular ejection fra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Cardiogenic Shock | Phase 3 | Status: RECRUITING